Quviviq vs DAYVIGO
both orexin receptor antagonists reviewed for insomnia
Quviviq
Idorsia Ltd · 1352 cited findings →
DAYVIGO(lemborexant)
Eisai Co., Ltd. · 1548 cited findings →
What the regulatory reviews say
Quviviq (daridorexant) and DAYVIGO (lemborexant) are both orexin receptor antagonists reviewed for the treatment of insomnia. Quviviq is indicated for adult patients with insomnia characterized by symptoms present for at least 3 months and considerable impact on daytime functioning. DAYVIGO is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, in adults.
In its review, Quviviq demonstrated a change from baseline in Wake After Sleep Onset (WASO) of -22.78 minutes and in Latency to Persistent Sleep (LPS) of -11.67 minutes, compared to placebo. DAYVIGO's review showed a LSGM ratio of sSOL (Month 6 / Baseline) for lemborexant 5 mg vs placebo of 0.73 and for lemborexant 10 mg vs placebo of 0.70. It also showed an LS Mean Treatment Difference in sWASO for lemborexant 5 mg vs placebo of -17.5 minutes and for lemborexant 10 mg vs placebo of -12.7 minutes.
It is crucial to note that these drugs were studied in separate trials with different designs, populations, endpoints, and timepoints. The figures presented are from each drug's own review documents and are not head-to-head comparisons. Therefore, neither drug is presented as superior to the other.
Each drug's own results — cited
| Quviviq | DAYVIGO | |
|---|---|---|
| Indication | the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning Adult patients with insomnia Idorsia Ltd — Quviviq FDA Review, p.2 | Treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, Population: Adults Adults with difficulties with sleep onset and/or sleep maintenance Eisai Co., Ltd. — Dayvigo FDA Review (NDA212028, ORIG 1, 201, p.149 |
| WASO change from baseline (vs placebo) | -22.78 LS mean difference vs placebo Idorsia Ltd — Quviviq FDA Review, p.62 | -17.5 LS Mean Treatment Difference in sWASO for lemborexant 5 mg vs placebo Eisai Co., Ltd. — Dayvigo FDA Review (NDA212028, ORIG 1, 201, p.156 |
| Incidence of somnolence/fatigue | 1 to 2% Depressive symptoms in patients taking daridorexant Idorsia Ltd — Quviviq FDA Review, p.27 | 6.9% Incidence of somnolence/fatigue for lemborexant 5 mg Eisai Co., Ltd. — Dayvigo FDA Review (NDA212028, ORIG 1, 201, p.30 |
Explore the full evidence
Every cited finding behind both drugs is in the Psychiatry research library →
Figures are as stated in the cited regulatory review documents. Educational reference only — not medical or investment advice.